RxDoctor Payments Data

Marc-Anthony Louis-Charles, MD

Family Medicine · Freeport, NYNPI 1790837714

Payments from drug & device makers

$911in general payments, 2019–2025

Across 48 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$574
  • AbbVie$127
  • AstraZeneca$74
  • Novo Nordisk$57
  • Bayer$20
  • Nestle Healthcare Nutrition Inc.$19
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$89198%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen29$574
AbbVie(2 entities)7$127
AstraZeneca5$74
Novo Nordisk2$57
Bayer1$20
Nestle Healthcare Nutrition Inc.1$19
Lilly USA, LLC1$15
GSK1$14
Johnson & Johnson1$11

How this compares

$911 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$10,392
Medicare patients
53
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate262$248,278
JardianceEmpagliflozin246$243,657
FarxigaDapagliflozin Propanediol48$59,427
EliquisApixaban44$46,306
VascepaIcosapent Ethyl97$43,176
Repatha SureclickEvolocumab33$39,368
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog87$30,267
OzempicSemaglutide18$27,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,131
XareltoRivaroxaban17$17,967
TrulicityDulaglutide14$17,624
TradjentaLinagliptin21$16,770
LinzessLinaclotide24$16,575
JanumetSitagliptin Phos/Metformin Hcl18$10,925
Novolog FlexpenInsulin Aspart35$5,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$74$59,42748 claims
Novo NordiskOzempic$57$27,62818 claims
GSKTrelegy Ellipta$14$24,13127 claims
Johnson & JohnsonXarelto$11$17,96717 claims
Lilly USA, LLCTrulicity$15$17,62414 claims
AbbVieLinzess$127$16,57524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Freeport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →